Partnership with world-leading animal health company

AKL Research and Development has partnered with a world-leading animal health company to test APPA in dogs

AKLRD has signed an agreement with one of the world’s top five animal health companies to fund the development of its next-stage clinical trial in canine OA. Osteoarthritis is the most common form of arthritis in dogs, affecting approximately a quarter of the population.

Under the terms of the agreement, AKLRD’s partner will fund a study in dogs with naturally occurring OA. The study will compare the efficacy and efficacy duration of the investigational drug APPA to the standard of care for treating canine OA. Currently, dogs with OA are usually treated with non-steroidal anti-inflammatory drugs (NSAIDs), such as meloxicam and carprofen. Common side effects of veterinary NSAIDs include vomiting, diarrhoea, not eating/eating less and lethargy while some may also be associated with gastrointestinal ulcers/perforations, and liver and kidney toxicity.


For more information click here.